Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

66 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors.
Rosen LS, Kurzrock R, Mulay M, Van Vugt A, Purdom M, Ng C, Silverman J, Koutsoukos A, Sun YN, Bass MB, Xu RY, Polverino A, Wiezorek JS, Chang DD, Benjamin R, Herbst RS. Rosen LS, et al. Among authors: polverino a. J Clin Oncol. 2007 Jun 10;25(17):2369-76. doi: 10.1200/JCO.2006.07.8170. J Clin Oncol. 2007. PMID: 17557949 Clinical Trial.
AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts.
Polverino A, Coxon A, Starnes C, Diaz Z, DeMelfi T, Wang L, Bready J, Estrada J, Cattley R, Kaufman S, Chen D, Gan Y, Kumar G, Meyer J, Neervannan S, Alva G, Talvenheimo J, Montestruque S, Tasker A, Patel V, Radinsky R, Kendall R. Polverino A, et al. Cancer Res. 2006 Sep 1;66(17):8715-21. doi: 10.1158/0008-5472.CAN-05-4665. Cancer Res. 2006. PMID: 16951187
Broad antitumor activity in breast cancer xenografts by motesanib, a highly selective, oral inhibitor of vascular endothelial growth factor, platelet-derived growth factor, and Kit receptors.
Coxon A, Bush T, Saffran D, Kaufman S, Belmontes B, Rex K, Hughes P, Caenepeel S, Rottman JB, Tasker A, Patel V, Kendall R, Radinsky R, Polverino A. Coxon A, et al. Among authors: polverino a. Clin Cancer Res. 2009 Jan 1;15(1):110-8. doi: 10.1158/1078-0432.CCR-08-1155. Clin Cancer Res. 2009. PMID: 19118038
Motesanib inhibits Kit mutations associated with gastrointestinal stromal tumors.
Caenepeel S, Renshaw-Gegg L, Baher A, Bush TL, Baron W, Juan T, Manoukian R, Tasker AS, Polverino A, Hughes PE. Caenepeel S, et al. Among authors: polverino a. J Exp Clin Cancer Res. 2010 Jul 15;29(1):96. doi: 10.1186/1756-9966-29-96. J Exp Clin Cancer Res. 2010. PMID: 20633291 Free PMC article.
Anti-tumor activity of motesanib in a medullary thyroid cancer model.
Coxon A, Bready J, Kaufman S, Estrada J, Osgood T, Canon J, Wang L, Radinsky R, Kendall R, Hughes P, Polverino A. Coxon A, et al. Among authors: polverino a. J Endocrinol Invest. 2012 Feb;35(2):181-90. doi: 10.3275/7609. Epub 2011 Mar 21. J Endocrinol Invest. 2012. PMID: 21422803
Discovery of N-phenyl nicotinamides as potent inhibitors of Kdr.
Dominguez C, Smith L, Huang Q, Yuan C, Ouyang X, Cai L, Chen P, Kim J, Harvey T, Syed R, Kim TS, Tasker A, Wang L, Zhang M, Coxon A, Bready J, Starnes C, Chen D, Gan Y, Neervannan S, Kumar G, Polverino A, Kendall R. Dominguez C, et al. Among authors: polverino a. Bioorg Med Chem Lett. 2007 Nov 1;17(21):6003-8. doi: 10.1016/j.bmcl.2007.07.077. Epub 2007 Aug 22. Bioorg Med Chem Lett. 2007. PMID: 17869515
Novel 2,3-dihydro-1,4-benzoxazines as potent and orally bioavailable inhibitors of tumor-driven angiogenesis.
La DS, Belzile J, Bready JV, Coxon A, DeMelfi T, Doerr N, Estrada J, Flynn JC, Flynn SR, Graceffa RF, Harriman SP, Larrow JF, Long AM, Martin MW, Morrison MJ, Patel VF, Roveto PM, Wang L, Weiss MM, Whittington DA, Teffera Y, Zhao Z, Polverino AJ, Harmange JC. La DS, et al. Among authors: polverino aj. J Med Chem. 2008 Mar 27;51(6):1695-705. doi: 10.1021/jm701129j. Epub 2008 Feb 27. J Med Chem. 2008. PMID: 18311900
Design, synthesis, and evaluation of orally active benzimidazoles and benzoxazoles as vascular endothelial growth factor-2 receptor tyrosine kinase inhibitors.
Potashman MH, Bready J, Coxon A, DeMelfi TM Jr, DiPietro L, Doerr N, Elbaum D, Estrada J, Gallant P, Germain J, Gu Y, Harmange JC, Kaufman SA, Kendall R, Kim JL, Kumar GN, Long AM, Neervannan S, Patel VF, Polverino A, Rose P, Plas Sv, Whittington D, Zanon R, Zhao H. Potashman MH, et al. Among authors: polverino a. J Med Chem. 2007 Sep 6;50(18):4351-73. doi: 10.1021/jm070034i. Epub 2007 Aug 15. J Med Chem. 2007. PMID: 17696416
66 results